Evidence map›Paper›PMID 34523049›Full record

ReviewCurrent atherosclerosis reports2021

The Role of Coronary Artery Calcium Testing for Value-Based Clinical Trials in Primary Prevention.

Emilio Fentanes, Miguel Cainzos Achirica, Khurram Nasir, Ron Blankstein

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current atherosclerosis reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Emilio FentanesDivision of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Miguel Cainzos AchiricaDivision on Cardiovascular Prevention and Wellness, Houston Methodist, Weill Cornell Medical College, Houston, TX, USA.
Khurram NasirDivision on Cardiovascular Prevention and Wellness, Houston Methodist, Weill Cornell Medical College, Houston, TX, USA.
Ron BlanksteinDivision of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA. rblankstein@bwh.harvard.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewReview the role of coronary artery calcium (CAC) testing in designing future clinical trials in primary prevention. RECENT

findingsWhile there are numerous new agents that have been found to lower cardiovascular event rates in clinical trials, these studies have required a large sample size, in part due to low event rates as well as improved baseline treatments. More precise risk assessment could allow for better identification of individuals who stand to derive the most benefit from various therapies. Coronary CAC testing offers a simple method for identifying high-risk primary prevention cohorts, and thus may allow for improved efficiency of clinical trials, enhanced efficacy of various therapies, and ultimately more favorable cost-effectiveness estimates. The use of CAC testing as part of the inclusion criteria used in clinical trials may result in identifying high-risk individuals who were previously not included in such studies while achieving favorable absolute risk reductions. The advantages afforded by using CAC to enrich clinical trials offer a potential road map for future clinical trials in primary prevention.

Indexed as

Coronary Artery DiseaseVascular CalcificationCalciumClinical Trials as TopicCoronary VesselsHumansPrimary PreventionRisk AssessmentRisk FactorsCalciumCoronary artery calciumPrimary preventionRoad mapValue-based clinical trials

Identifiers

PMID34523049

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.